Integrating incretin-based therapies into comprehensive obesity care: an EASO position statement
The Lancet Regional Health - Europe, cilt.70, 2026 (SCI-Expanded, SSCI, Scopus)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 70
- Basım Tarihi: 2026
- Doi Numarası: 10.1016/j.lanepe.2026.101840
- Dergi Adı: The Lancet Regional Health - Europe
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Social Sciences Citation Index (SSCI), Scopus, BIOSIS, EMBASE, Directory of Open Access Journals
- Anahtar Kelimeler: Chronic disease management, GLP-1 receptor agonists, Incretin-based therapies, Multidisciplinary care, Obesity
- İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır
Özet
Incretin-based therapies have transformed obesity treatment, producing substantial weight loss and benefits across cardiometabolic outcomes. However, translating therapeutic efficacy into sustainable population-level benefit remains challenging across European healthcare systems that vary in workforce capability, multidisciplinary care, reimbursement, access, and monitoring infrastructure. We describe this mismatch as the EASO Integration Paradox: therapeutic innovation has advanced more rapidly than the health-system structures required for its optimal, equitable, and sustainable implementation. In this EASO Position Statement, we propose the EASO Integration Framework, a model for integrating incretin-based therapies into comprehensive obesity care. The framework is organized around five interdependent pillars: Right Patient, Right Care, Right Workforce, Right Data, and Right Access. We also outline a European research and implementation agenda focused on real-world evidence, harmonised monitoring, workforce development, pharmacovigilance, and equitable access. The challenge is no longer whether incretin-based therapies should be used, but how they should be implemented responsibly within comprehensive obesity care pathways.